NeuroPhage Pharmaceuticals Garners $12,400,000 Series B Financing

  • Feed Type
  • Date
    3/1/2011
  • Company Name
    NeuroPhage Pharmaceuticals
  • Mailing Address
    222 3rd St. Cambridge, MA 02142
  • Company Description
    NeuroPhage is developing a breakthrough protein dissaggregation platform for treatment of neurodegenerative diseases. Our lead Alzheimer’s disease (AD) drug candidate, NPT001, safely and effectively dissaggregates existing Aß plaque in preclinical animal models, which is unique among disease-modifying approaches for AD.
  • Website
    http://www.neurophage.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $12,400,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The financing will be mostly directed to the IND-enabling activities in preparation of a Phase 1 clinical trial for NPT001, NeuroPhage’s lead product candidate for the treatment of Alzheimer’s disease, and include further work to expand the platform.
  • M&A Terms
  • Venture Investor
    bioMerieux
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.